Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
Sign Up to like & getrecommendations! Published in 2018 at "Current Cardiology Reports"
DOI: 10.1007/s11886-018-1051-2
Abstract: Purpose of ReviewMimetics and analogs that extend the half-life of native glucagon-like peptide-1 (GLP-1), i.e., glucagon-like peptide-1 receptor agonists (GLP-1 RAs), at therapeutic doses, are indicated as adjuncts to diet and exercise, to improve glycemic… read more here.
Keywords: reduction; risk; glucagon like; glp ras ... See more keywords
Cardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes
Sign Up to like & getrecommendations! Published in 2018 at "Current Diabetes Reports"
DOI: 10.1007/s11892-018-1043-z
Abstract: Purpose of ReviewGlucagon-like peptide-1 receptor agonists (GLP-1 RAs) have positive effects on weight loss, blood pressure, hyperlipidemia, and glycemic control. They exhibit a broad range of effects on the cardiovascular system that are independent of… read more here.
Keywords: patients type; risk; glp ras; receptor agonists ... See more keywords
Once-Daily Oral Semaglutide Versus Injectable GLP-1 RAs in People with Type 2 Diabetes Inadequately Controlled on Basal Insulin: Systematic Review and Network Meta-analysis
Sign Up to like & getrecommendations! Published in 2021 at "Diabetes Therapy"
DOI: 10.1007/s13300-021-01034-w
Abstract: The relative efficacy and safety of once-daily oral semaglutide vs. injectable glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in subjects with type 2 diabetes (T2D) inadequately controlled on basal insulin were assessed using network meta-analysis (NMA).… read more here.
Keywords: semaglutide; glp ras; basal insulin; oral semaglutide ... See more keywords
Higher Rates of Persistence and Adherence in Patients with Type 2 Diabetes Initiating Once-Weekly vs Daily Injectable Glucagon-Like Peptide-1 Receptor Agonists in US Clinical Practice (STAY Study)
Sign Up to like & getrecommendations! Published in 2021 at "Diabetes Therapy"
DOI: 10.1007/s13300-021-01189-6
Abstract: Introduction Reducing dosing frequency may lower treatment burden and improve persistence and adherence. This retrospective, observational study assessed persistence and adherence in patients with type 2 diabetes (T2D) initiating once-weekly or daily injectable glucagon-like peptide-1… read more here.
Keywords: group; type diabetes; persistence adherence; glp ras ... See more keywords
Efficacy of dulaglutide after switching from incretin-related drugs in patients with type 2 diabetes and inadequate glycemic control
Sign Up to like & getrecommendations! Published in 2021 at "Diabetology International"
DOI: 10.1007/s13340-021-00508-3
Abstract: Aims The efficacy of dulaglutide was assessed according to the pretreatments administered before the initiation of dulaglutide in patients with type 2 diabetes. Methods In total, 89 patients treated using dulaglutide (0.75 mg, once a weekly)… read more here.
Keywords: group; type diabetes; daily glp; glp ras ... See more keywords
Treating cognitive impairment in schizophrenia with GLP-1RAs: an overview of their therapeutic potential
Sign Up to like & getrecommendations! Published in 2021 at "Expert Opinion on Investigational Drugs"
DOI: 10.1080/13543784.2021.1951702
Abstract: ABSTRACT Introduction Schizophrenia is a neuropsychiatric disorder that affects approximately 1% of individuals worldwide. There are no available medications to treat cognitive impairment in this patient population currently. Preclinical evidence suggests that glucagon-like peptide-1 receptor… read more here.
Keywords: schizophrenia; glp ras; glp; cognitive impairment ... See more keywords
Glucagon-Like Peptide-1 Receptor Agonists and Risk of Anaphylactic Reaction Among Patients With Type 2 Diabetes: Multisite Population-Based Cohort Study.
Sign Up to like & getrecommendations! Published in 2022 at "American journal of epidemiology"
DOI: 10.1093/aje/kwac021
Abstract: Case reports and a pharmacovigilance analysis have linked glucagon-like peptide-1 receptor agonists (GLP-1 RAs) with anaphylactic reactions, but real-world evidence for this possible association is lacking. Using databases from the United Kingdom (Clinical Practice Research… read more here.
Keywords: reaction; glp ras; risk anaphylactic; glucagon like ... See more keywords
Cardiovascular effects of incretins - focus on GLP-1 receptor agonists.
Sign Up to like & getrecommendations! Published in 2022 at "Cardiovascular research"
DOI: 10.1093/cvr/cvac112
Abstract: GLP-1 receptor agonists (GLP-1 RAs) have been used to treat patients with type 2 diabetes since 2005 and have become popular because of the efficacy and durability in relation to glycaemic control in combination with… read more here.
Keywords: receptor agonists; glp receptor; glp ras; type diabetes ... See more keywords
Glucagon‐like peptide‐1 receptor agonists and microvascular outcomes in type 2 diabetes: A systematic review and meta‐analysis
Sign Up to like & getrecommendations! Published in 2019 at "Diabetes"
DOI: 10.1111/dom.13484
Abstract: We conducted a systematic review and meta‐analysis of randomized controlled trials to assess the effect of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) on microvascular endpoints in adult patients with type 2 diabetes. We included 60… read more here.
Keywords: glucagon like; review meta; glp ras; systematic review ... See more keywords
Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride
Sign Up to like & getrecommendations! Published in 2021 at "Cardiovascular Diabetology"
DOI: 10.1186/s12933-021-01431-2
Abstract: Background Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) leads to multiple metabolic changes, reduction in glucose levels and body weight are well established. In people with type 2 diabetes, GLP-1 RAs reduce the risk… read more here.
Keywords: liraglutide glimepiride; treatment; disease; metabolism ... See more keywords
Novel Insights into the Roles and Mechanisms of GLP-1 Receptor Agonists against Aging-Related Diseases
Sign Up to like & getrecommendations! Published in 2022 at "Aging and Disease"
DOI: 10.14336/ad.2021.0928
Abstract: Aging and aging-related diseases have emerged as increasingly severe health and social problems. Therefore, it is imperative to discover novel and effective therapeutics to delay the aging process and to manage aging-related diseases. Glucagon-like peptide-1… read more here.
Keywords: receptor agonists; glp ras; related diseases; aging related ... See more keywords